论文部分内容阅读
头孢普齐(cefprozil,商品名cefzil)是FDA于1991年底批准上市的口服头孢类抗生素。该药是由顺反异构体以90:10的比例组成的混合体。本品口服吸收迅速且完全,t_(max),1～2h(口服)0.5h(静注);C_(max)和Auc随剂量而增加;口服 0.25～1.0g的C_(max)可高达18μg/ml,静注达13～48μg/ml;t_(1/2)约1.5h,原形尿回收率约60～80％,且不随剂量而改变;血清蛋白结合率36～44％,分布体积为0.17～0.23L/kg;肾CL1.78～2.53ml/(min·kg);少量经胆汁排泄及代谢。肝功能不良对本品药动学无明显
Cefprozil (cefzil) is the oral cephalosporin antibiotic approved by the FDA at the end of 1991. This medicine is a mixture of cis and trans isomers in a 90:10 ratio. The oral absorption of this product quickly and completely, t_ (max), 1 ~ 2h (oral) 0.5h (intravenous); C_ (max) and Auc increased with dose; oral 0.25 ~ 1.0g of C max up to 18μg / ml, intravenous injection of 13 ~ 48μg / ml; t_ (1/2) of about 1.5h, urine recovery of about 60 ~ 80%, and does not change with the dose; serum protein binding rate of 36 ~ 44% 0.17 ~ 0.23L / kg; renal CL1.78 ~ 2.53ml / (min · kg); a small amount of bile excretion and metabolism. Hepatic dysfunction on the pharmacokinetics of this product was not obvious